Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AKRX is in the long-term up 276% in 24 years.
Description: Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, vaccines, and others. The company operates in three segments: Ophthalmic, Hospital Drugs & Injectables, and Contract Services. The Ophthalmic segment markets diagnostic products, such as mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others for use in the office setting; therapeutic products, including antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; non-pharmaceutical products comprising artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers; and over-the-counter dry eye and
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||1.68||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||151.41%||Sales Growth - Q/Q||71.65%||P/E||19.93|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||1.85%||ROE||9.14%||ROI|
|Current Ratio||3.68||Quick Ratio||2.71||Long Term Debt/Equity||3.1||Debt Ratio||0.35|
|Gross Margin||50.18%||Operating Margin||16.31%||Net Profit Margin||5.96%||Dividend Payout Ratio|
|Cash From Financing Activities||972.31 M||Cash From Investing Activities||-966.54 M||Cash From Operating Activities||30.92 M||Gross Profit||128.38 M|
|Net Profit||34.23 M||Operating Profit||71.91 M||Total Assets||1.91 B||Total Current Assets||494.33 M|
|Total Current Liabilities||134.16 M||Total Debt||1.12 B||Total Liabilities||1.52 B||Total Revenue||227.83 M|
|High 52 week||33.56||Low 52 week||3.33||Last close||3.64||Last change||-5.94%|
|RSI||48.76||Average true range||0.32||Beta||0.93||Volume||2.35 M|
|Simple moving average 20 days||-0.15%||Simple moving average 50 days||-30.37%||Simple moving average 200 days||-72.33%|
|Performance Week||4.6%||Performance Month||-17.65%||Performance Quart||-41.85%||Performance Half||-74.07%|
|Performance Year||-89.13%||Performance Year-to-date||7.37%||Volatility daily||5.48%||Volatility weekly||12.26%|
|Volatility monthly||25.12%||Volatility yearly||87.01%||Relative Volume||219.78%||Average Volume||3.71 M|
|New High||New Low|
2019-08-14 15:30:05 | Is Akorn NASDAQ:AKRX A Risky Investment?
2019-08-05 16:15:04 | Edited Transcript of AKRX earnings conference call or presentation 1-Aug-19 1:00pm GMT
2019-08-02 07:24:08 | Akorn AKRX Q2 2019 Earnings Call Transcript
2019-08-01 08:55:12 | Akorn AKRX Reports Q2 Loss, Tops Revenue Estimates
2019-07-25 10:33:02 | Analysts Estimate Akorn AKRX to Report a Decline in Earnings: What to Look Out for
2019-07-11 16:32:15 | Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call
2019-07-09 08:02:30 | See what the IHS Markit Score report has to say about Akorn Inc.
2019-06-28 07:00:00 | Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%
2019-06-27 11:20:30 | Did Hedge Funds Drop The Ball On Akorn, Inc. AKRX ?
2019-06-25 11:00:52 | Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues
2019-06-25 10:32:09 | Akorn gets FDA warning letter for another manufacturing plant
2019-06-25 09:41:21 | Akorn Files Complaint on Fresenius' Canceled Bid
2019-06-25 08:17:00 | Drugmaker Akorn Receives FDA Warning Letter Regarding N.J. Facility
2019-06-25 08:08:11 | UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant
2019-06-25 07:44:00 | Generics maker Akorn receives warning letter from the FDA relating to NJ facility
2019-06-25 07:35:00 | Akorn Receives FDA Warning Letter
2019-06-14 07:01:32 | How Many Akorn, Inc. NASDAQ:AKRX Shares Did Insiders Buy, In The Last Year?
2019-06-10 08:03:20 | See what the IHS Markit Score report has to say about Akorn Inc.
2019-06-01 08:08:16 | See what the IHS Markit Score report has to say about Akorn Inc.
2019-05-30 08:04:09 | See what the IHS Markit Score report has to say about Akorn Inc.
2019-05-30 07:59:05 | Akorn to Present at the Jefferies 2019 Global Healthcare Conference
2019-05-21 09:02:54 | See what the IHS Markit Score report has to say about Akorn Inc.
2019-05-20 16:05:00 | Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
2019-05-20 08:01:33 | Akorn to Present at the RBC Capital Markets Healthcare Conference
2019-05-12 21:49:44 | Here’s What Hedge Funds Think About Akorn, Inc. AKRX
2019-05-08 09:24:51 | Akorn AKRX Q1 2019 Earnings Call Transcript
2019-05-07 17:00:59 | Edited Transcript of AKRX earnings conference call or presentation 7-May-19 2:00pm GMT
2019-05-07 08:35:12 | Akorn AKRX Reports Q1 Loss, Tops Revenue Estimates
2019-05-07 08:02:58 | See what the IHS Markit Score report has to say about Akorn Inc.
2019-05-07 07:24:26 | Akorn: 1Q Earnings Snapshot
2019-05-07 07:05:00 | Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance
2019-04-24 09:14:21 | Introducing Akorn NASDAQ:AKRX, The Stock That Tanked 89%
2019-04-22 15:00:00 | FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC
2019-04-22 12:58:02 | Here's Why Akorn Stock Rose as Much as 14.4% Today
2019-04-22 11:09:17 | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-04-22 09:58:00 | FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC
2019-04-22 09:28:24 | Akorn Receives 2 Generic Nose Spray Approvals
2019-04-19 18:00:00 | 3-Day Deadline Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-04-19 17:36:17 | Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI
2019-04-18 17:00:00 | Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
2019-04-18 13:40:00 | 4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-04-18 10:57:00 | AKRX, HIIQ & AMRN - Class Action Deadline Bronstein, Gewirtz & Grossman, LLC